Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
暂无分享,去创建一个
C. Jenkins | B. Celli | J. Vestbo | J. Yates | P. Calverley | Julie A. Anderson | P. Jones | G. Ferguson | L. Willits | J. Anderson
[1] M. Decramer,et al. The Effect of Tiotropium on COPD GOLD Stage II during the Four-Year UPLIFT Trial. , 2009, ATS 2009.
[2] Does pharmacotherapy reduce the rate of decline of lung function in COPD? , 2009, American journal of respiratory and critical care medicine.
[3] P. Calverley,et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.
[4] T. Seemungal,et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.
[5] N. Zhong,et al. The Efficacy and Safety of Combination Salmeterol (50 μg)/Fluticasone Propionate (500 μg) Inhalation Twice Daily Via Accuhaler in Chinese Patients With COPD , 2007 .
[6] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[7] R. Pauwels,et al. The severity of airways obstruction as a determinant of treatment response in COPD , 2006, International journal of chronic obstructive pulmonary disease.
[8] C. Jenkins,et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol , 2004, European Respiratory Journal.
[9] R. Pauwels,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Updated 2003 , 2004, COPD.
[10] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[11] N. Hanania,et al. The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .
[12] S. Spencer,et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.
[13] R. Pauwels,et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.
[14] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[15] N. Hanania,et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. , 2003, Chest.
[16] J. Yates,et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.